Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/3816
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorINCA-
dc.contributor.authorSistema Único de Saúde (Brasil)-
dc.contributor.authorBrasil. Ministério da Saúde-
dc.date.accessioned2021-08-31T17:30:50Z-
dc.date.available2021-08-31T17:30:50Z-
dc.date.issued2021-06-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/3816-
dc.description2 p.-
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.relation.ispartofseriesAno V, n. 49.-
dc.subjectMieloma Múltiplopt_BR
dc.subjectQuimioterapiapt_BR
dc.subjectTratamento Farmacológico-
dc.subjectDrug Therapy-
dc.subjectMultiple Myeloma-
dc.subjectMieloma Múltiple-
dc.titleQuimioterapia do mieloma múltiplopt_BR
dc.TypeRevistas/Boletinspt_BR
Appears in Collections:Informe SUS - ONCO 2021

Files in This Item:
File Description SizeFormat 
informe-sus-onco-junho-2021.pdf482.59 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.